Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports (2018)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1097/MD.0000000000013517
- Subjects: IMUNOTERAPIA; CARCINOMA; NEOPLASIAS DO CÓRTEX SUPRARRENAL; METÁSTASE NEOPLÁSICA
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2018
- Source:
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
MOTA, Jose Mauricio et al. Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports. Medicine, v. 97, n. 52, 2018Tradução . . Disponível em: https://doi.org/10.1097/MD.0000000000013517. Acesso em: 20 fev. 2026. -
APA
Mota, J. M., Sousa, L. G., Braghiroli, M. I., Siqueira, L. T., Bezerra Neto, J. E., Chapchap, P., et al. (2018). Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports. Medicine, 97( 52). doi:10.1097/MD.0000000000013517 -
NLM
Mota JM, Sousa LG, Braghiroli MI, Siqueira LT, Bezerra Neto JE, Chapchap P, Hoff AA de O, Hoff PM. Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports [Internet]. Medicine. 2018 ; 97( 52):[citado 2026 fev. 20 ] Available from: https://doi.org/10.1097/MD.0000000000013517 -
Vancouver
Mota JM, Sousa LG, Braghiroli MI, Siqueira LT, Bezerra Neto JE, Chapchap P, Hoff AA de O, Hoff PM. Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports [Internet]. Medicine. 2018 ; 97( 52):[citado 2026 fev. 20 ] Available from: https://doi.org/10.1097/MD.0000000000013517 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre o DOI: 10.1097/MD.0000000000013517 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
